FIT Biotech Oy
Company release March 29, 2018 at 8:30 pm EET
Correction to company release March 29, 2018 - FIT Biotech Oy's Board of Directors has decided on the issue of Convertible Notes and Warrants - authorization to issue warrants
The Company's Board of Directors decided on March 29, 2018 to draw down the third tranche of EUR 500,000 included in the Alpha Blue Ocean funding Programme. In relation to the draw down the Company issued 500 Convertible Notes and was expected to issue also 468,750,000 share warrants. The authorisation granted by the Extraordinary General Meeting on February 6, 2018 however, allows the Board to issue only 87,500,000 warrants. The Board shall propose that the Annual General Meeting on April 14, 2018 decides upon and grants additional authorisations to the Board in order to carry on the implementation of the Programme in accordance with its terms.
FIT BIOTECH OY
Board of Directors
For further information:
CEO Erkki Pekkarinen
Tel: +358 44 027 0080
Certified Advisor: Aalto Capital Partners Oy, tel. +358 40 587 7000
About FIT Biotech
FIT Biotech Oy is a biotechnology company established in 1995. The company develops and licenses its patented GTU® (Gene Transport Unit) vector technology for new-generation medical treatments. GTU® is a gene transport technology that meets an important medical challenge in the usability of gene therapy and DNA vaccines.
FIT Biotech applies GTU® technology in its drug development programmes. Application areas include cancer (gene therapy) and infectious diseases such as HIV and tuberculosis, as well as animal vaccines.
FIT Biotech shares are listed on the First North Finland marketplace maintained by Nasdaq Helsinki Oy.
NASDAQ OMX Helsinki